The multiplex bead array approach to identifying serum biomarkers associated with breast cancer

Kim, Byoung Kwon; Lee, Jong Won; Park, Pil Je; Shin, Yong Sam; Lee, Won Young; Lee, Kyung Ae; Ye, Sena; Hyun, Heesun; Kang, Kyung Nam; Yeo, Donghwa; Kim, Youngdai; Ohn, Sung Yup; Noh, Dong Young; Kim, Chul Woo

doi:10.1186/bcr2247

Cited by 112 publications

(94 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This adhesion protein has also been identified as a serum marker in other types of tumors including breast cancer37 and hepatocellular carcinoma 38. VN is a glycoprotein involved in cell adhesion, extracellular matrix remodeling and in tumor cell migration, principally through its interaction with integrins, the urokinase‐type plasminogen activator receptor (uPAR) and plasminogen activator inhibitor‐1 (PAI‐1) 39. VN has not been studied as a serum marker associated with melanoma prognosis to date; however, VN receptor expression on melanoma cells has been associated with poor disease prognosis 15, 40.…”

Section: Discussionmentioning

confidence: 99%

Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma

Ortega-Martinez

Gardeazábal

Erramuzpe

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

Like many cancers, an early diagnosis of melanoma is fundamental to ensure a good prognosis, although an important proportion of stage I–II patients may still develop metastasis during follow‐up. The aim of this work was to discover serum biomarkers in patients diagnosed with primary melanoma that identify those at a high risk of developing metastasis during the follow‐up period. Proteomic and mass spectrophotometry analysis was performed on serum obtained from patients who developed metastasis during the first years after surgery for primary tumors and compared with that from patients who remained disease‐free for more than 10 years after surgery. Five proteins were selected for validation as prognostic factors in 348 melanoma patients and 100 controls by ELISA: serum amyloid A and clusterin; immune system proteins; the cell adhesion molecules plakoglobin and vitronectin and the antimicrobial protein dermcidin. Compared to healthy controls, melanoma patients have high serum levels of these proteins at the moment of melanoma diagnosis, although the specific values were not related to the histopathological stage of the tumors. However, an analysis based on classification together with multivariate statistics showed that tumor stage, vitronectin and dermcidin levels were associated with the metastatic progression of patients with early‐stage melanoma. Although melanoma patients have increased serum dermcidin levels, the REPTree classifier showed that levels of dermcidin <2.98 μg/ml predict metastasis in AJCC stage II patients. These data suggest that vitronectin and dermcidin are potent biomarkers of prognosis, which may help to improve the personalized medical care of melanoma patients and their survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma

Ortega-Martinez

Gardeazábal

Erramuzpe

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…This protein has been noted as having a protective effect in breast cancer by facilitating transport of vitamin D metabolites (13) and has been shown to be downregulated in the serum of breast cancer patients (26). Some studies suggest that specific genetic variants of VDBP influence a woman's risk of developing breast cancer (27).…”

Section: Discussionmentioning

confidence: 99%

Proteomic Changes Induced by Effective Chemopreventive Ratios of n-3:n-6 Fatty Acids and Tamoxifen against MNU-Induced Mammary Cancer in the Rat

Skibinski

Thompson

Das

et al. 2013

Cancer Prevention Research

View full text Add to dashboard Cite

We used a proteomic approach to gain insights into the mechanisms of protection at the protein level by a high n-3:n-6 ratio in the absence and presence of Tamoxifen. Four groups were treated with 1-methyl-1-nitrosourea (MNU) and fed the following diets with varied n-3:n-6 ratios; group 1 ¼ 1:1; groups 2 and 3 ¼ 10:1 and 25:1, respectively; group 4: (25:1) plus Tamoxifen (1 mg/kg diet). The plasma from six rats/group was pooled and analyzed with the isobaric tags for relative and absolute quantitation method; 148 proteins were identified with 95% confidence by ProteinPilot 4.0. In plasma of rats fed 10:1, 25:1 n-3:n-6, and 25:1 plus Tamoxifen, the number of proteins that met our criteria (P 0.05, error factor 2) were 10, 14, and 19 proteins, respectively. Selected proteins were further validated by Western blotting. Compared to 1:1, both 10:1 and 25:1 diets upregulated vitamin D binding protein, gelsolin, and 14-3-3 sigma, reported to have tumor suppressive effects, whereas alpha-1B-glycoprotein, which has been reported to be elevated in the serum of breast cancer patients was decreased. Compared to 25:1, the 25:1 plus Tamoxifen diet downregulated apolipoprotein E, haptoglobin, and inter-a-inhibitor H4 heavy chain. Ingenuity pathway analysis determined that the trends of specific proteins were related to lipid metabolism in the 25:1 n-3:n-6 group, whereas the 25:1 n-3:n-6 plus Tamoxifen group included proteins involved in cancer and inflammation. Our results show that several proteins were altered in a manner consistent with chemoprevention. Such proteins may serve as biomarkers to monitor efficacy of n-3 and Tamoxifen in future clinical chemoprevention trials. Cancer Prev Res; 6(9); 979-88. Ó2013 AACR.

show abstract

“…More detailed information can be obtained from elsewhere (Angenendt et al, 2006;Diamandis, 2003;Haab, 2005;Kim et al, 2009;Petricoin et al, 2002). A relatively new proteomic technique that is suitable for high-throughput profiling is Surface Enhanced Laser Desorption/Ionization-Time-Of-Flight (SELDI-TOF) which combines affinity chromatography on a modified surface (surface-enhanced) with MALDI-TOF.…”

Section: Other Proteomic Methodsmentioning

confidence: 99%

Glioma Proteomics: Methods and Current Perspective

Somasundaram¹,

Nijaguna²,

Kumar³

2011

Brain Tumors - Current and Emerging Therapeutic Strategies

View full text Add to dashboard Cite

The multiplex bead array approach to identifying serum biomarkers associated with breast cancer

Cited by 112 publications

References 57 publications

Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma

Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma

Proteomic Changes Induced by Effective Chemopreventive Ratios of n-3:n-6 Fatty Acids and Tamoxifen against MNU-Induced Mammary Cancer in the Rat

Glioma Proteomics: Methods and Current Perspective

Contact Info

Product

Resources

About